Moreover, the majority of human cancers have either mutations in the RB1 gene, or mutations in other genes in the RB pathway that result in a functionally inactivated RB, such as increased expression of cyclin D, CDK4 or CDK6 or silencing of the CDK inhibitor p16 [11]. Here, RB1 is linked to cancer.